Table 1.
Human Cell Lines Used in This Study
| Cell line | Donor sex (age)⁎ | Special characteristics | References† |
|---|---|---|---|
| Epidermal keratinocyte | |||
| Strain N | M (0) | Normal | 1, 30–33 |
| N/HPV16E6E7 | M (0) | Immortal; p53- and pRb-deficient | 1, 31 |
| N/HPV16E6 | M (0) | All E6 functions, including p53-deficiency | |
| N/HPV16E6 (JH26 mutant) | M (0) | p53 normal but has other E6 functions | |
| N/HPV16E7 | M (0) | All E7 functions, including Rb-deficiency | 30 |
| N/p53DD/cdk4R24C | M (0) | p53-deficient and p16INK4A-resistant | 34 |
| N/TERT1 | M (0) | Immortal; loss of ability to express p16INK4A and p14ARF | 1, 30, 31 |
| N/TERT1/EGFRΔ (E746-A750) | M (0) | Immortal; EGF-independent for growth | |
| N/TERT1/HRAS (G12V) | M (0) | Immortal; EGF-independent for growth; Lamγ2 overexpressing | |
| N/TERT1/cRAF1 (22W) | M (0) | Immortal; EGF-independent for growth; Lamγ2 overexpressing | |
| N/TERT1/MEK1 (DD) | M (0) | Immortal; EGF-independent for growth; Lamγ2 overexpressing | |
| G5Ep | M (0) | Normal | 35 |
| O5Ep | M (0) | Normal | |
| Epidermal SCC | |||
| SCC-13 | F (56) | p16- and p53-deficient; immortal; tumorigenic | 31–33, 36, 37 |
| Oral keratinocyte | |||
| OKF6 | M (57) | Normal | 30 |
| Dysplastic oral keratinocyte | |||
| POE9n | M (65) | Homozygous deletion of p16INK4A and p14ARF; p53-deficient, nontumorigenic | 30, 31 |
| D17 | ND (ND) | p16INK4A-deficient; normal p53; nontumorigenic | 38, 39 |
| Oral SCC | |||
| SCC-15 | M (55) | p16- and p53-deficient; immortal; tumorigenic | 32, 36, 37 |
| SCC-25 | M (74) | p16- and p53-deficient; immortal; tumorigenic | 32, 36, 37 |
| SCC-68 | M (ND) | p16- and p53-deficient; immortal; tumorigenic | |
| SCC-71 | M (80) | p16- and p53-deficient; immortal; tumorigenic | 31, 36 |
F, female; M, male; ND, no data.
⁎
Ages are given in years; 0 indicates newborn.
†
References for derivation and characterization of previously published cell lines.